spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Ubiquigent Appoints Dr Sheelagh Frame, CSO, to Its Board of Directors

Ubiquigent

New Board appointment supports Ubiquigent’s pursuit of novel DUB modulators as new therapeutics to address areas of high unmet medical need


Dundee, UK, 24 October 2022:
Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitylase (DUB) modulators as powerful new therapeutics, today announced the appointment of Dr Sheelagh Frame, Chief Scientific Officer (CSO), to the Company’s Board of Directors. The appointment comes at a key stage in the Company’s development with the growing importance of the DUBs in drug discovery and will help drive the progress of Ubiquigent’s internal portfolio of novel DUB modulators, associated drug discovery programmes and commercial services.

Sheelagh joined Ubiquigent in 2018 as Head of Biology, before being promoted to CSO in 2021. During her time at Ubiquigent, Sheelagh has grown the team and operational capacity, expanded the suite of biochemical and cellular assays comprising its DUB-focused drug discovery platform, and progressed an IP portfolio of novel DUB modulators. She has over 25 years’ experience in drug discovery and development, having gained significant expertise on key drug targets in her previous roles as Program Manager and Translational Research Team Manager at Cyclacel Limited, primarily in oncology, but also spanning inflammation, diabetes, and rare diseases. Sheelagh has contributed to more than 50 scientific publications and completed her postdoctoral research at Onyx Pharmaceuticals, where she supported the validation and development of kinase inhibitors for anti-cancer therapy. She holds a PhD in Medicine from the Beatson Institute for Cancer Research, affiliated with the University of Glasgow, and a BSc in Molecular Biology from the University of Edinburgh.

Dr Sheelagh Frame, CSO, Ubiquigent, said: “DUBs are rapidly emerging as exciting new drug targets to achieve targeted protein degradation and stabilisation. Ubiquigent sits at the forefront of the DUB space, and I am delighted to be joining the Board at such an important time as we progress novel modalities that exploit DUBs and the UPS towards clinical realisation.”

Jason Mundin, CEO, Ubiquigent, commented: “Sheelagh has made a tremendous contribution to Ubiquigent since joining us in 2018. I am extremely pleased that she has now joined our Board and look forward to continuing to work with her as Ubiquigent enters the next stage of its development.”

Dr Mark Treherne, Chairman of the Board, Ubiquigent, added: “We are so pleased to welcome Sheelagh to the Board, bringing with her a wealth of impressive achievements and her close ties with the R&D and Operational teams in Dundee. We are confident that Sheelagh’s contributions will continue to significantly advance our core mission of enabling DUB-focused drug discovery and development for areas of high unmet medical need, especially as we focus on developing our in-house drug discovery pipeline.”

In recognition of her inspiring contributions to science and business, Sheelagh has recently been shortlisted for the Women’s Business Club Awards in the C-suite category, Scotland.
To find out more, visit https://womensbusiness.club/awards.
phone +44 (0) 1382 472654
email services@ubiquigent.com
web https://www.ubiquigent.com/about-us/contact/
email University Incubator Dundee Technopole James Lindsay Place Dundee DD1 5JJ Scotland, UK
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Gerresheimer AG and Stevanato Group present EZ-fill Smart™, a new and innovative Ready-To-Fill Vial Platform Gerresheimer AG and Stevanato Group present EZ-fill Smart™, a new and innovative Ready-To-Fill Vial Platform

Two leading companies introduce EZ-fill Smart™, the new Ready-To-Fill solution platform for the global vial market. Customers benefit from reduced Total Cost of Ownership, lower process complexity and accelerated speed to market. The new platform ensures higher product quality and enhanced process sustainability by introducing an alternative sterilization method.
More info >>


White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

Aigenpulse

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement